Colon cancer, version 1.2017: Clinical practice guidelines in oncology

Al B. Benson; Alan P. Venook; Lynette Cederquist; Emily Chan; Yi Jen Chen; Harry S. Cooper; Dustin Deming; Paul F. Engstrom; Peter C. Enzinger; Alessandro Fichera; Jean L. Grem; Axel Grothey; Howard S. Hochster; Sarah Hoffe; Steven Hunt; Ahmed Kamel; Natalie Kirilcuk; Smitha Krishnamurthi; Wells A. Messersmith; Mary F. Mulcahy; James D. Murphy; Steven Nurkin; Leonard Saltz; Sunil Sharma; David Shibata; John M. Skibber; Constantinos T. Sofocleous; Elena M. Stoffel; Eden Stotsky-Himelfarb; Christopher G. Willett; Christina S. Wu; Kristina M. Gregory; Deborah Freedman-Cass

doi:10.6004/jnccn.2017.0036

Colon cancer, version 1.2017: Clinical practice guidelines in oncology

Al B. Benson, Alan P. Venook, Lynette Cederquist, Emily Chan, Yi Jen Chen, Harry S. Cooper, Dustin Deming, Paul F. Engstrom, Peter C. Enzinger, Alessandro Fichera, Jean L. Grem, Axel Grothey, Howard S. Hochster, Sarah Hoffe, Steven Hunt, Ahmed Kamel, Natalie Kirilcuk, Smitha Krishnamurthi, Wells A. Messersmith, Mary F. MulcahyJames D. Murphy, Steven Nurkin, Leonard Saltz, Sunil Sharma, David Shibata, John M. Skibber, Constantinos T. Sofocleous, Elena M. Stoffel, Eden Stotsky-Himelfarb, Christopher G. Willett, Christina S. Wu, Kristina M. Gregory, Deborah Freedman-Cass

Medical Oncology

Research output: Contribution to journal › Review article › peer-review

386 Scopus citations

Abstract

This portion of the NCCN Guidelines for Colon Cancer focuses on the use of systemic therapy in metastatic disease. Considerations for treatment selection among 32 different monotherapies and combination regimens in up to 7 lines of therapy have included treatment history, extent of disease, goals of treatment, the efficacy and toxicity profiles of the regimens, KRAS/NRAS mutational status, and patient comorbidities and preferences. Location of the primary tumor, the BRAF mutation status, and tumor microsatellite stability should also be considered in treatment decisions.

Original language	English (US)
Pages (from-to)	370-398
Number of pages	29
Journal	JNCCN Journal of the National Comprehensive Cancer Network
Volume	15
Issue number	3
DOIs	https://doi.org/10.6004/jnccn.2017.0036
State	Published - Mar 1 2017

ASJC Scopus subject areas

Oncology

Access to Document

10.6004/jnccn.2017.0036

Cite this

Benson, A. B., Venook, A. P., Cederquist, L., Chan, E., Chen, Y. J., Cooper, H. S., Deming, D., Engstrom, P. F., Enzinger, P. C., Fichera, A., Grem, J. L., Grothey, A., Hochster, H. S., Hoffe, S., Hunt, S., Kamel, A., Kirilcuk, N., Krishnamurthi, S., Messersmith, W. A., ... Freedman-Cass, D. (2017). Colon cancer, version 1.2017: Clinical practice guidelines in oncology. JNCCN Journal of the National Comprehensive Cancer Network, 15(3), 370-398. https://doi.org/10.6004/jnccn.2017.0036

Benson, AB, Venook, AP, Cederquist, L, Chan, E, Chen, YJ, Cooper, HS, Deming, D, Engstrom, PF, Enzinger, PC, Fichera, A, Grem, JL, Grothey, A, Hochster, HS, Hoffe, S, Hunt, S, Kamel, A, Kirilcuk, N, Krishnamurthi, S, Messersmith, WA, Mulcahy, MF, Murphy, JD, Nurkin, S, Saltz, L, Sharma, S, Shibata, D, Skibber, JM, Sofocleous, CT, Stoffel, EM, Stotsky-Himelfarb, E, Willett, CG, Wu, CS, Gregory, KM & Freedman-Cass, D 2017, 'Colon cancer, version 1.2017: Clinical practice guidelines in oncology', JNCCN Journal of the National Comprehensive Cancer Network, vol. 15, no. 3, pp. 370-398. https://doi.org/10.6004/jnccn.2017.0036

@article{d55797990a4a49c19a6b3cd2519a74cc,

title = "Colon cancer, version 1.2017: Clinical practice guidelines in oncology",

abstract = "This portion of the NCCN Guidelines for Colon Cancer focuses on the use of systemic therapy in metastatic disease. Considerations for treatment selection among 32 different monotherapies and combination regimens in up to 7 lines of therapy have included treatment history, extent of disease, goals of treatment, the efficacy and toxicity profiles of the regimens, KRAS/NRAS mutational status, and patient comorbidities and preferences. Location of the primary tumor, the BRAF mutation status, and tumor microsatellite stability should also be considered in treatment decisions.",

author = "Benson, {Al B.} and Venook, {Alan P.} and Lynette Cederquist and Emily Chan and Chen, {Yi Jen} and Cooper, {Harry S.} and Dustin Deming and Engstrom, {Paul F.} and Enzinger, {Peter C.} and Alessandro Fichera and Grem, {Jean L.} and Axel Grothey and Hochster, {Howard S.} and Sarah Hoffe and Steven Hunt and Ahmed Kamel and Natalie Kirilcuk and Smitha Krishnamurthi and Messersmith, {Wells A.} and Mulcahy, {Mary F.} and Murphy, {James D.} and Steven Nurkin and Leonard Saltz and Sunil Sharma and David Shibata and Skibber, {John M.} and Sofocleous, {Constantinos T.} and Stoffel, {Elena M.} and Eden Stotsky-Himelfarb and Willett, {Christopher G.} and Wu, {Christina S.} and Gregory, {Kristina M.} and Deborah Freedman-Cass",

year = "2017",

month = mar,

day = "1",

doi = "10.6004/jnccn.2017.0036",

language = "English (US)",

volume = "15",

pages = "370--398",

journal = "JNCCN Journal of the National Comprehensive Cancer Network",

issn = "1540-1405",

publisher = "Cold Spring Publishing LLC",

number = "3",

}

TY - JOUR

T1 - Colon cancer, version 1.2017

T2 - Clinical practice guidelines in oncology

AU - Benson, Al B.

AU - Venook, Alan P.

AU - Cederquist, Lynette

AU - Chan, Emily

AU - Chen, Yi Jen

AU - Cooper, Harry S.

AU - Deming, Dustin

AU - Engstrom, Paul F.

AU - Enzinger, Peter C.

AU - Fichera, Alessandro

AU - Grem, Jean L.

AU - Grothey, Axel

AU - Hochster, Howard S.

AU - Hoffe, Sarah

AU - Hunt, Steven

AU - Kamel, Ahmed

AU - Kirilcuk, Natalie

AU - Krishnamurthi, Smitha

AU - Messersmith, Wells A.

AU - Mulcahy, Mary F.

AU - Murphy, James D.

AU - Nurkin, Steven

AU - Saltz, Leonard

AU - Sharma, Sunil

AU - Shibata, David

AU - Skibber, John M.

AU - Sofocleous, Constantinos T.

AU - Stoffel, Elena M.

AU - Stotsky-Himelfarb, Eden

AU - Willett, Christopher G.

AU - Wu, Christina S.

AU - Gregory, Kristina M.

AU - Freedman-Cass, Deborah

PY - 2017/3/1

Y1 - 2017/3/1

N2 - This portion of the NCCN Guidelines for Colon Cancer focuses on the use of systemic therapy in metastatic disease. Considerations for treatment selection among 32 different monotherapies and combination regimens in up to 7 lines of therapy have included treatment history, extent of disease, goals of treatment, the efficacy and toxicity profiles of the regimens, KRAS/NRAS mutational status, and patient comorbidities and preferences. Location of the primary tumor, the BRAF mutation status, and tumor microsatellite stability should also be considered in treatment decisions.

AB - This portion of the NCCN Guidelines for Colon Cancer focuses on the use of systemic therapy in metastatic disease. Considerations for treatment selection among 32 different monotherapies and combination regimens in up to 7 lines of therapy have included treatment history, extent of disease, goals of treatment, the efficacy and toxicity profiles of the regimens, KRAS/NRAS mutational status, and patient comorbidities and preferences. Location of the primary tumor, the BRAF mutation status, and tumor microsatellite stability should also be considered in treatment decisions.

UR - http://www.scopus.com/inward/record.url?scp=85016215716&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85016215716&partnerID=8YFLogxK

U2 - 10.6004/jnccn.2017.0036

DO - 10.6004/jnccn.2017.0036

M3 - Review article

C2 - 28275037

AN - SCOPUS:85016215716

SN - 1540-1405

VL - 15

SP - 370

EP - 398

JO - JNCCN Journal of the National Comprehensive Cancer Network

JF - JNCCN Journal of the National Comprehensive Cancer Network

IS - 3

ER -

Colon cancer, version 1.2017: Clinical practice guidelines in oncology

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this